Featured ArticlesRosaceaThe Latest

Review Highlights Need for More Effective Rosacea Treatments

By February 1, 2021May 25th, 2021No Comments

Featured Article

Featured Article

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others”

More Rosacea Articles

“The inflammatory pathways underlying rosacea are becoming increasingly elucidated. What remains unknown is the mechanism of progression of these pathways, and how they can result in papules/pustules and/or phyma in some patients but not others.”

Heather Onorati

While much progress has been made in better understanding the pathogenesis of rosacea, a need remains for more effective treatments to address the underlying inflammation and to improve clearance.

Current therapies for facial erythema provide temporary relief and are not consistent at helping patients achieve complete clearance of papules and pustules, according to authors Jerry Tan, MD, of Western University in Ontario, Canada, and J. Mark Jackson, MD, of the University of Louisville in Louisville, Ky, who published a review in the Journal of Drugs in Dermatology (“Treating Inflammation in Rosacea: Current Options and Unmet Needs”). They examined what is known about the underlying inflammatory nature of rosacea and its available treatments.

Ideally, the future of rosacea treatment should include addressing both the papules and pustules  as well as the inflammatory pathways leading to erythema and phyma, the authors say. Longer-term control and the ability to reduce the signs and symptoms of rosacea would be an important advance, they write.

Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry

Discover new clinical findings in Rosacea.  View the latest articles, case reports, supplements, Editorials,  and more.

 

You May Also Like

WATCH VIDEO ABSTRACT: Scarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols

| Featured Articles, JDD Highlights, The Latest | No Comments
Click Here to View Video Abstract Importance: Managing chronic conditions is an essential aspect of dermatologic care, especially regarding the resolution of inflammatory dermatologic disease and recovery of skin lesions. Short-term…

WATCH VIDEO ABSTRACT: Assessing Implicit Bias in Dermatology

| Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Click Here to Watch Video Abstract   Background: Patients with skin of color (SOC), defined as Fitzpatrick skin types IV to VI, and of varying ethnicities are under-represented in dermatology. This…

JDD in the News: Increased Dose of Adalimumab in Overweight, Obese Patients; Topical for Infantile Hemangiomas

| Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Healio covered a JDD study on the impact of an increased dose of adalimumab in hidradenitis suppurativa patients who are overweight or obese. Researchers from the University of California San…

Leave a Reply